Renke
Latest round
- Angel
Last raised
- Sep 2022
Total raised
- Undisclosed
Investors
- 3
About Renke
Founded in 2021 and based in Beijing, China, Renke is a biotech company that develops genomics and tumor genetic testing technologies. Xun Lan, the founder of the company, has more than ten years of experience in multi-omics research and early cancer screening research. The company's main products are pan-cancer early screening products. Its products cover from early screening of tumors, mid-stage diagnosis, to late-stage treatment and monitoring. Pan-cancer early screening products can detect cancers such as stomach and lung cancers.
Who invested in Renke
3 investors across 1 round
See all investors in Renke
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Sep 22, 2022
Amount
Undisclosed
Investors
Questions about Renke
Who invested in Renke?
Renke has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Renke raised?
Renke has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Renke last raise money?
Renke's most recent round on record is a Angel, in Sep 2022.
What does Renke do?
Founded in 2021 and based in Beijing, China, Renke is a biotech company that develops genomics and tumor genetic testing technologies.
Where is Renke headquartered?
Renke is headquartered in Beijing, China.
Which VCs invest in companies like Renke?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at Renke's stage. Their profiles are linked below.
VCs backing biotechnology startups at Angel
Raising like Renke? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.